In a large study, there were lower odds of neonatal mortality associated with vaccination.
COVID-19 vaccine protection lasts at least six months after second dose
Feb 07, 2023
Vaccine effectiveness against death was lower for patients aged 80 years and older.
Intention to receive COVID-19 vaccine has grown faster among Black adults
Feb 02, 2022
A persistent lower vaccination rate in Black adults might be explained by other factors besides hesitancy.
Vaccination cuts risk for myocardial infarction, stroke after COVID-19
Jul 29, 2022
The findings show a lower hospitalization risk 31 to 120 days after COVID-19 infection.
mRNA COVID-19 efficacy lower for immunocompromised adults
Nov 04, 2021
Vaccine effectiveness of two doses of mRNA vaccine lower against COVID-19-associated hospitalization, with variation by condition. mRNA vaccines approved to fight COVID-19 in the U.S. include Pfizer-BioNTech...
CDC: Vaccinated more likely to die during omicron wave if they got J&J shot
Mar 25, 2022
However, breakthrough infections among J&J vaccine recipients were similar or lower compared with the other vaccines.
Prior SARS-CoV-2 infection ups protection for vaccinated
Nov 15, 2021
Prior infection was linked to a lower risk for breakthrough infection among individuals vaccinated with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna).
FDA approves first RSV vaccine
May 03, 2023
Arexvy was ~82% effective in preventing RSV-induced lower respiratory tract infections in adults aged 60 or more years.
Age, cancer type affect COVID-19 vaccine uptake in cancer patients
Mar 16, 2023
Higher rates of vaccination were seen in older patients; lower rates were seen for metastatic solid tumors, with comorbidities.
Risk for breakthrough SARS-CoV-2 infection lower with mRNA-1273
Feb 02, 2022
The risk for breakthrough infection and of 60-day hospitalization was significantly lower for mRNA-1273 (Moderna) versus BNT162b2 (Pfizer-BioNTech) vaccination.